Clinical Trial Update: Efficacy and Safety of Dalpiciclib Plus Toremifene in the Treatment of Advanced First-line HR Positive and HER2 Negative Breast Cancer: a Multicenter, Single Arm, Exploratory Phase II Clinical Study [Phase 2]

View source ↗

Summary

A multicenter, single-arm Phase II trial assessing dalpiciclib in combination with toremifene for first-line advanced hormone receptor-positive, HER2-negative b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Toremifene (toremifene)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: CANCER, BRAEST CANCER | Phase 2 | Status: NOT_YET_RECRUITING